re: accumulation Yes it was a long time ago that they first...

re: accumulation Yes it was a long time ago that they first tried at China:

http://www.asx.com.au/asxpdf/20060704/pdf/3xf4f7cypl43g.pdf

http://www.asx.com.au/asxpdf/20061109/pdf/3zhkndgkwrnr4.pdf

This was when the share price was in the 40c range and over 200m(?) fully diluted shares on issue (not sure what the options prices were).

I am not a long term investor- I am a short termer. I see value in short term potential, such as the fact that the product may never make profits, but along the way there will be various value-adding announcements.

If they can change the prototype modelling, get a Chinese third party on board (which they have) then if claw back a small percentage of where the market cap was back in 2006, there will be value added for current shareholders.

http://www.asx.com.au/asxpdf/20130820/pdf/42hshbts5rbpwj.pdf

This above doesn't take into account the new therapeutic company acquisition which adds a totally different dimension to SBN but reflects their focus of close-to-commercialisation products.

IMO reviving the Oraline product is definitely worth a shot.